Research analyst, medium-term horizon, biotech, small-cap

Newly Nasdaq-Listed Immune Pharma Offers Big Upside

On August 14, 2014, Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) announced financial results for the second quarter 2014. For the quarter, the company reported no revenues with a net loss of $0.4 million, or $0.03 per share. Net loss for the quarter included $2.0 million in G&A expenses and $1.0 million in R&D expenses. The company reported non-operating income of $3.3 million, mainly due to a decrease in the value of the derivative warrants issued in March 2014.

Immune exited the second quarter 2014 with $3.2 million in cash and cash equivalents. We remind investors that in April 2014, Immune entered into a three-year, $5.0 million revolving line of credit with an existing stockholder, who is related to a member...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details